⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2024Open Access

Supplementary Figure S7 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers

Patricia J. Keller Elizabeth J. Adams Rentian Wu Alexandre Côté Shilpi Arora Nico Cantone Rosana Meyer Jennifer A. Mertz Victor Gehling Jike Cui Jacob I. Stuckey Avinash Khanna Feng Zhao Zehua Chen Ziyang Yu Richard Cummings Mohammed Taimi Nehal J. Lakhani Drew Rasco Martin Gutierrez Linda Duska Michael Devitt Ronda Rippley Julian Levell Jennifer Truong Jing Wang Kaiming Sun Patrick Trojer

View Full Paper

Ask AI

Bookmark

Share

Abstract

In cancer patients tulmimetostat plasma exposure levels correlate with PRC2 target gene expression changes in peripheral blood.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Keller et al. (2024) studied this question.

synapsesocial.com/papers/68e5e0e0b6db643587574c09 https://doi.org/10.1158/0008-5472.26423909

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S7 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers2024
2Supplementary Figure S4 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers2024
3Supplementary Figure S4 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers2024
4Supplementary Figure S3 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers2024
5Supplementary Figure S3 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers2024

More related papers

Supplementary Figure S6 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers2024
Supplementary Figure S6 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers2024
Supplementary Figure S1 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers2024